Nebenwirkungen · Xofigo
Xofigo 1100 kBq/mL solution for injection · Abschnitt 4.8 · PDF-Seite 8
HOS-128201 · Präparat HOS-096525
Neutropenia (all grades) was reported in 5% of patients treated with Xofigo and in 1% of patients receiving placebo. Grade 3 and 4 neutropenia was observed in 2.2% of patients treated with Xofigo and in 0.7% of patients receiving placebo. Overall, the frequency of grade 3 and 4 neutropenia was lower in patients that did not previously receive docetaxel (0.8% in patients treated with Xofigo versus 0.8% in patients receiving placebo) compared to patients that previously received docetaxel (3.2% in patients treated with Xofigo versus 0.6% in patients receiving placebo).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-30T14:59:00Z · SHA-256 2bc8e88ff62751c132e9d1a925ea99cae9b2a2bdea846ae42676e4b50d70bb74 · Passage 88826b16f6d9ca5f6a218d134d323006ee5cc9d5893b470cf4925970f618b39a · Zeichen 3390–3963 im Abschnitt